Discovery Program
Autoimmunity
Key Facts
About Greywolf Therapeutics
Greywolf Therapeutics is a private, preclinical-to-clinical stage biotech based in Oxford, UK, developing a first-in-class therapeutic approach focused on modulating Signal 1 of the T cell activation cascade. The company's core technology involves small molecules that 'flick a switch' inside cells to alter their antigen presentation, thereby enabling or suppressing T cell recognition. With a lead oncology candidate (GRWD5769) showing proof-of-mechanism in Phase 1/2 trials and active discovery programs in autoimmunity and virology, Greywolf is positioning itself as a pioneer in a new therapeutic branch of immunology. The company is pre-revenue and backed by an expert team focused on addressing significant unmet medical need through fundamental immune system retuning.
View full company profileAbout Greywolf Therapeutics
Greywolf Therapeutics is a private, preclinical-to-clinical stage biotech based in Oxford, UK, developing a first-in-class therapeutic approach focused on modulating Signal 1 of the T cell activation cascade. The company's core technology involves small molecules that 'flick a switch' inside cells to alter their antigen presentation, thereby enabling or suppressing T cell recognition. With a lead oncology candidate (GRWD5769) showing proof-of-mechanism in Phase 1/2 trials and active discovery programs in autoimmunity and virology, Greywolf is positioning itself as a pioneer in a new therapeutic branch of immunology. The company is pre-revenue and backed by an expert team focused on addressing significant unmet medical need through fundamental immune system retuning.
View full company profileAbout Disco Pharmaceuticals
Disco Pharmaceuticals is a private, pre-clinical stage biotech based in Berlin, Germany, pioneering a novel approach to oncology drug discovery through comprehensive mapping of the cancer cell surfaceome. The company has secured a €36 million seed financing round and is led by a seasoned team with deep experience in oncology, company building, and business development. Its core technology aims to identify previously inaccessible protein targets and communities to enable the development of highly specific antibody therapeutics, positioning it to address significant gaps in targeted cancer therapy.
View full company profileAbout Disco Pharmaceuticals
Disco Pharmaceuticals is a private, pre-clinical stage biotech based in Berlin, Germany, pioneering a novel approach to oncology drug discovery through comprehensive mapping of the cancer cell surfaceome. The company has secured a €36 million seed financing round and is led by a seasoned team with deep experience in oncology, company building, and business development. Its core technology aims to identify previously inaccessible protein targets and communities to enable the development of highly specific antibody therapeutics, positioning it to address significant gaps in targeted cancer therapy.
View full company profileAbout reMYND
reMYND is a private, clinical-stage biotech developing novel oral therapeutics targeting synaptic and neuronal dysfunction in Alzheimer's and Huntington's disease. Its lead asset, REM392, is an oral small molecule designed to restore calcium homeostasis to provide both symptomatic and disease-modifying benefits in Alzheimer's. The company leverages a dual-strategy business model, combining internal drug development with a revenue-generating CRO service that validates its scientific platform and funds R&D.
View full company profileTherapeutic Areas
Other Autoimmunity Drugs
| Drug | Company | Phase |
|---|---|---|
| Adimune | Aditx Therapeutics | Platform / Asset |